The promising alliance of anti-cancer electrochemotherapy with immunotherapy.
The promising alliance of anti-cancer electrochemotherapy with immunotherapy.
复制标题
DOI：
10.1007/s10555-016-9615-3
复制
发表时间：
2016-06
期刊：
影响因子：
--
通讯作者：
Mir LM
中科院分区：
文献类型：
--
作者：
Calvet CY;Mir LM
抗肿瘤电化学疗法，即通过电穿孔增加抗癌药物的摄取，目前已在欧洲约140个癌症治疗中心植入。它的使用得到了英国国家健康与护理卓越研究所的支持，用于皮肤转移的姑息治疗，截至2015年底，约有13，000名癌症患者接受了这项技术的治疗。现在的努力集中在将这种局部抗肿瘤治疗转变为系统性治疗。电基因疗法，即电穿孔介导的治疗基因的转移，目前正在进行临床评估，并带来了兴奋，以扩大抗癌医疗设备。在有前途的电基因治疗策略中，DNA疫苗接种和基于精氨酸的免疫治疗旨在刺激抗肿瘤免疫。本文综述了电化学疗法和基因电疗法的研究兴趣和发展现状。然后，我们强调了电化学疗法与免疫疗法（如免疫检查点抑制剂或基于电基因疗法的策略）相结合的潜在有益结果，以同时实现出色的局部减瘤抗肿瘤反应和全身抗转移作用。
Anti-tumor electrochemotherapy, which consists in increasing anti-cancer drug uptake by means of electroporation, is now implanted in about 140 cancer treatment centers in Europe. Its use is supported by the English National Institute for Health and Care Excellence for the palliative treatment of skin metastases, and about 13,000 cancer patients were treated by this technology by the end of 2015. Efforts are now focused on turning this local anti-tumor treatment into a systemic one. Electrogenetherapy, that is the electroporation-mediated transfer of therapeutic genes, is currently under clinical evaluation and has brought excitement to enlarge the anti-cancer armamentarium. Among the promising electrogenetherapy strategies, DNA vaccination and cytokine-based immunotherapy aim at stimulating anti-tumor immunity. We review here the interests and state of development of both electrochemotherapy and electrogenetherapy. We then emphasize the potent beneficial outcome of the combination of electrochemotherapy with immunotherapy, such as immune checkpoint inhibitors or strategies based on electrogenetherapy, to simultaneously achieve excellent local debulking anti-tumor responses and systemic anti-metastatic effects.